Geneseeq

Founded in 2012 and based in downtown Toronto with an additional headquarters in Nanjing, China, Geneseeq provides advanced genomic testing services tailored for precision oncology. The company offers a range of services including pan-cancer panels that analyze over 400 genes, as well as cancer-type specific gene panels. These services are enhanced by the use of next-generation sequencing technologies, which allow for high-quality genomic data with a fast turnaround time, crucial for accelerating translational research. Geneseeq employs over 30 dedicated staff in Toronto and more than 1500 across China. It has a significant impact on the field of oncology, having published over 550 translational research papers in peer-reviewed journals. The company’s products and services are utilized by more than 8,000 oncologists from over 800 hospitals across 25 provinces in China. Geneseeq boasts a testing capacity of over 250,000 samples per year and is actively engaged in over 2,000 translational research projects. It also supports over 60 biopharmaceutical companies in their clinical trials. Additionally, Geneseeq offers comprehensive genomic profiling for all solid tumors and hematologic malignancies, aiding in clinical diagnosis, treatment decision-making, and monitoring of minimal residual disease.